EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Research

• Publication date

  2013-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-13-0044PMID 23966292PMCID PMC3823187
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues

  2013cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway.

  2012cited by this paper
• Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.

  2012cited by this paper
• Targeting Homologous Recombination Repair in Cancer

  2012cited by this paper
• Systematic identification of genomic markers of drug sensitivity in cancer cells

  2012cited by this paper
• Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway

  2011cited by this paper
• In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status.

  2011cited by this paper
• DNA interstrand crosslink repair and cancer

  2011cited by this paper
• EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.

  2011cited by this paper
• Mechanism of RAD51-Dependent DNA Interstrand Cross-Link Repair

  2011cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• A Swiss army knife of DNA interstrand crosslink repair

  2011cited by this paper
• EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.

  2011cited by this paper
• FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.

  2011cited by this paper
• FANCP/SLX4

  2011cited by this paper
• First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

  2010cited by this paper
• FAN1 Acts with FANCI-FANCD2 to Promote DNA Interstrand Cross-Link Repair

  2010cited by this paper
• Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer

  2010cited by this paper
• DNA interstrand crosslink repair in mammalian cells: step by step

  2010cited by this paper
• Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2.

  2010cited by this paper
• A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair.

  2010cited by this paper
• Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy

  2010cited by this paper
• Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies

  2009cited by this paper
• The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links

  2009cited by this paper
• Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  2009cited by this paper
• An Oncogene-Induced DNA Damage Model for Cancer Development

  2008cited by this paper
• Biomarkers and Mechanisms of FANCD2 Function

  2008cited by this paper
• Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.

  2008cited by this paper
• AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51.

  2008cited by this paper
• EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.

  2008cited by this paper
• Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma.

  2007cited by this paper
• Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors

  2007cited by this paper
• Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

  2007cited by this paper
• Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair

  2006cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.

  2005cited by this paper
• Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase*

  2005cited by this paper
• Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair.

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae.

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2004cited by this paper
• Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.

  2001cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• Genotoxicity assessment of waste products of aluminum plasma etching with the SOS chromotest.

  1993cited by this paper
• Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics.

  1993cited by this paper

• Coopting germline BRCA2 mutation with an available PARP inhibitor to manage resistance to EGFR targeted therapy in EGFR-mutated lung cancer: combination of olaparib with osimertinib

  2026cites this paper
• PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor.

  2025cites this paper
• Potentiation of EGFR mutant lung cancer treatment targeting replication stress

  2025cites this paper
• Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency

  2023cites this paper
• ATM participates in fine particulate matter‐induced airway inflammation through regulating DNA damage and DNA damage response

  2023cites this paper
• Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers

  2023cites this paper
• Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.

  2023cites this paper
• Key Considerations in Targeted Protein Degradation Drug Discovery and Development

  2022cites this paper
• Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.

  2021cites this paper
• Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy

  2021cites this paper
• Identification of a Novel Gene Model-Based Homologous Recombination Deficiency Score to Improve Survival Prediction of TNBC.

  2021cites this paper
• Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy.

  2021cites this paper
• Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.

  2020cites this paper
• Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation

  2020cites this paper
• A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

  2020cites this paper
• SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma

  2020cites this paper
• Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).

  2020cites this paper
• Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

  2020cites this paper
• Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

  2019influential citation
• Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization

  2019cites this paper
• EGFR exon 19‐deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non‐small cell lung cancer

  2019cites this paper
• Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer

  2019cites this paper
• Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.

  2019cites this paper
• Applying Precision Oncology Principles in Radiation Oncology.

  2018cites this paper
• PARP inhibitors as precision medicine for cancer treatment

  2017cites this paper
• Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells

  2017cites this paper
• EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork–Associated DNA Damage Repair

  2017influential citation
• Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors

  2016cites this paper
• PARP inhibitor combination therapy.

  2016cites this paper
• Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation.

  2016cites this paper
• Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis

  2016cites this paper
• Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

  2016cites this paper
• Molecular determinants of radiation response in non-small cell lung cancer.

  2015cites this paper
• Chapter 1. General introduction

  2015cites this paper
• Radiotherapy in the Era of Precision Medicine.

  2015cites this paper
• Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation.

  2015cites this paper
• DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

  2015cites this paper
• Structural insights into 5′ flap DNA unwinding and incision by the human FAN1 dimer

  2014cites this paper
• Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.

  2014cites this paper
• Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography

  2014cites this paper